Harmony Biosciences Holdings, Inc. (HRMY) P/B ratio
Harmony Biosciences Holdings, Inc. (HRMY) trades at 2.2× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.5×. That is 16.7% lower than the 3.0× of fiscal 2024. Figures as of 18 Nov 2026, 12:28 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/B ratio today
- 2.2×
- P/B ratio, fiscal 2025
- 2.5×
- Change on fiscal 2024
- −16.7%
- Highest on record
- 13.5×fiscal 2021
- Lowest on record
- 2.5×fiscal 2025
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Harmony Biosciences Holdings, Inc. P/B ratio, in more detail
Today's figure is 11.8% below the fiscal 2025 year-end.
Across the 6 fiscal year-ends on record (2020–2025), the highest was 13.5× in fiscal 2021 and the lowest 2.5× in fiscal 2025. Today's P/B ratio is at or below every one of the 6 fiscal year-ends on record; their median is 6.3×.
P/B ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Harmony Biosciences Holdings, Inc. P/B ratio, year by year
| Fiscal year | P/B ratio | Change | Year ended | Share price at year-end | Book value per share |
|---|---|---|---|---|---|
| Today | 2.2× | — | $33.01 | — | |
| 2025 | 2.5× | 16.7% down | $37.42 | $14.86 | |
| 2024 | 3.0× | 27.7% down | $34.41 | $11.39 | |
| 2023 | 4.2× | 50.0% down | $32.30 | $7.74 | |
| 2022 | 8.4× | 38.3% down | $55.10 | $6.59 | |
| 2021 | 13.5× | 41.2% up | $42.64 | $3.15 | |
| 2020 | 9.6× | — | $36.15 | $3.77 | |
| 2019 | — | — | — | -$54.37 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.
How to read it
It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.
Harmony Biosciences Holdings, Inc., figure by figure
- Harmony Biosciences Holdings, Inc. market cap
- Harmony Biosciences Holdings, Inc. revenue
- Harmony Biosciences Holdings, Inc. earnings
- Harmony Biosciences Holdings, Inc. earnings per share (EPS)
- Harmony Biosciences Holdings, Inc. P/E ratio
- Harmony Biosciences Holdings, Inc. P/S ratio
- Harmony Biosciences Holdings, Inc. free cash flow
- Harmony Biosciences Holdings, Inc. operating margin
- Harmony Biosciences Holdings, Inc. dividend
- Harmony Biosciences Holdings, Inc. shares outstanding
- Harmony Biosciences Holdings, Inc. total debt
- Harmony Biosciences Holdings, Inc. cash on hand
- Harmony Biosciences Holdings, Inc. total assets
- Harmony Biosciences Holdings, Inc. return on equity (ROE)
- Harmony Biosciences Holdings, Inc. return on invested capital (ROIC)
Harmony Biosciences Holdings, Inc. (HRMY) overview: price, valuation and scorecard
Harmony Biosciences Holdings, Inc. P/B ratio: questions and answers
What is Harmony Biosciences Holdings, Inc.'s P/B ratio?
Harmony Biosciences Holdings, Inc. (HRMY) trades at 2.2× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 2.5×. That is 16.7% lower than the 3.0× of fiscal 2024.
Is Harmony Biosciences Holdings, Inc.'s P/B ratio high or low compared with its own history?
Today's P/B ratio is at or below every one of the 6 fiscal year-ends on record; their median is 6.3×.
What are the highest and lowest P/B ratio figures on record for Harmony Biosciences Holdings, Inc.?
Across the 6 fiscal year-ends on record (2020–2025), the highest was 13.5× in fiscal 2021 and the lowest 2.5× in fiscal 2025.
How is Harmony Biosciences Holdings, Inc.'s P/B ratio calculated?
The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Harmony Biosciences Holdings, Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/B ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Piotroski F-score: the nine tests and what they show
The Piotroski F-score is a 0–9 count of simple accounting tests a company passes: four on profitability, three on debt, liquidity and share issuance, two on operating efficiency. Joseph Piotroski's 2000 paper found that among cheap, high book-to-market stocks, high scorers went on to beat low scorers. It is a screen of financial health, not a valuation.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Harmony Biosciences Holdings, Inc. (HRMY) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/HRMY/pb-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.